Identification
- Generic Name
- rhGAD65
- DrugBank Accession Number
- DB04963
- Background
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- Recombinant human GAD65
- Recombinant human glutamic acid decarboxylase
Pharmacology
- Indication
Investigated for use/treatment in diabetes mellitus type 1.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
The immune system of patients treated with rhGAD65 demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with rhGAD65 therapy and subjects receiving rhGAD65 show an up regulation of cytokines in response to GAD65.
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Diamyd
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- I7YY5T4995
- CAS number
- Not Available
References
- General References
- Bekris LM, Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen AL, Lernmark A, Robertson JA, Hampe CS: GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med. 2007 May;24(5):521-6. Epub 2007 Mar 15. [Article]
- External Links
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52